Rituximab

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Product Specifications

CAS Number

[174722-31-7]

Product Name Alternative

Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8

UNSPSC

12352203

Hazard Statement

H372

Target

CD20; Radionuclide-Drug Conjugates (RDCs)

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Rituximab.html

Purity

99.85

Solubility

H2O

Smiles

[Rituximab]

Molecular Weight

(143.47 kDa)

Precautions

P260-P264-P270-P501

References & Citations

[1]Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12 (2) :341-50.|[2]Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101 (3) :949-54.|[3]Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99 (3) :1038-43.